엑세스바이오

950130KOSDAQ의료용품 및 기타 의약 관련제품 제조업

48.0 / 100

Reference Date: 2026-06-10

Financial Score16.0 / 40

News Sentiment20.0 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Plunged 19.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

AccessBio develops and sells diagnostic products based on in-vitro diagnostics (IVD) technologies, focusing on infectious disease rapid diagnostic tests (RDTs) for malaria, influenza, and COVID-19. Its COVID-19 diagnostic products, which received FDA Emergency Use Authorization, have become a major revenue driver, with the company expanding globally amid growing IVD market demand.

Number of Employees

75people

Average Salary

159.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.194.0Point

PBR

—Industry Average 1.303.5Point

ROE

-14.02Industry Average -4.893.5Point

2.9x industry avg (excellent)

Debt Ratio

4.40Industry Average 6.865.0Point

Lower than industry avg (good)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼71.2% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼727.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -5.0% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 80

Positive
[클리니컬 히스토리] 엑세스바이오, 변이 대응 확인…키트 재가동 시.....
엑세스바이오의 변이 대응 진단키트 유효성 확인으로 코로나19 진단 시장의 잠재력이 재평가되고 있다.
Positive
코로나19 변이 '시카다'에도 진단 유효…엑세스바이오, "공백 없다"
엑세스바이오의 코로나19 항원진단키트가 변이 바이러스 '시카다'에도 효과적으로 진단함으로써 시장 경쟁력을 강화했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 2,580Won52-week high 5,09052-week low 2,580

1-month return0.0Point

1m -19.00% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15